|
Jay Tischfield (born June 15,1946) is MacMillan Professor II and the Founding Chair of the Department of Genetics at Rutgers University.〔(The Tischfield’s Lab homepage )〕 He is also Professor of Pediatrics and Psychiatry at Rutgers. He is currently Director of the Human Genetics Institute of New Jersey. He also is the CEO and scientific director of RUCDR Infinite Biologics® https://en.wikipedia.org/w/index.php?title=Jay_Tischfield&action=edit&editintro=Template:BLP_editintro# http://genetics.rutgers.edu/component/comprofiler/userprofile/jay?Itemid=101 (formerly the Rutgers University Cell & DNA Repository), the largest university-based repository in the world that collects, processes and performs genomic assays on human samples.〔(The Rutgers University Cell & DNA repository )〕 Tischfield has six U.S patents to his name.〔(United States Patent and Trademark Office )〕 ==Education and career== Professor Tischfield obtained his bachelor’s degree in biology in 1967 at the City University of New York, Brooklyn College. He finished his master’s degree in biology at Yale University in 1969, where he received his PhD in 1973. At Yale, Tischfield worked on mapping human genes to chromosomes. He used mice-man somatic cell hybrids to determine which genes are located on which chromosomes. He identified the gene for indophenol oxidase in mammals.〔 (Y. H. Tan, J. Tischfield , and F. H. Ruddle: The linkage of genes for the human interferon-induced antiviral protein and indophenol oxidase-B traits to chromosome G-21, ''The Journal of Experimental Medicine'', Vol 137, 317-330 )〕 Later, this gene was identified by researchers from Duke University as the gene coding for the enzyme superoxide dismutase,〔(History of Superoxide dismutase gene discovery in Pubmed )〕 which is involved in Down syndrome and some cases of Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig’s disease). Professor Tischfield is a diplomate of the American Board of Medical Genetics in PhD Medical Genetics and Clinical Molecular Genetics. He is a Founding Fellow of the American College of Medical Genetics. Professor Tischfield’s research at Rutgers University focuses on the genetic basis of complex diseases that are caused by many genes, frequently in combination, and often triggered by environmental causes. Tischfield’s lab investigates (), alcohol addiction and dihydroxyadenine urolithiasis and cystinuria, kidney diseases characterized by severe kidney stones. The laboratory has developed knockout mouse models for both kidney stone diseases and is developing therapies.〔(Jay Tischfield’s lab )〕 Another research area is focused on loss of heterozygosity, a side effect of DNA-repair and recombination. Via this mechanism, tumor suppressor genes can be deactivated, leading to cancer. Tischfield’s group uses population studies to find genes that are involved in diseases, using samples from the RUCDR Infinite Biologics. In the past, the RUCDR contributed samples to a research project concerning the genetic causes of progeria.〔(The Progeria Research Foundation’s Cell and Tissue Bank )〕 This study revealed that progeria patients have a defect in the Lamin A gene on chromosome 1.〔(M. Eriksson et al. (2003). "Recurrent de novo point mutations in lamin A cause Hutchinson–Gilford progeria syndrome". Nature 423: 293–298 )〕 The discovery led to a clinical drug trial with a farnesyl transferase inhibitor, that started in May 2007. In recent years Tischfield's research has turned to the genetic basis neuropsychaitric disorders such as Autism, Tourette syndrome and Obsessive Compulsive Disorder, three disorders on which he has coauthored publications. Professor Tischfield's role has extended from science to University and New Jersey State politics and in 2011 NJBIZ listed Tischfield as being the 85th most powerful person in New Jersey business because of his political influence.〔(NJBIZ The 100 most powerful people in New Jersey business )〕 抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』 ■ウィキペディアで「Jay Tischfield」の詳細全文を読む スポンサード リンク
|